Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

Prescription volume for specialty medications, not price hikes, largely seems to be the main factor in the ongoing huge ...

the white paper underscores a widespread crisis of underappreciation, operational strain and burnout, directly impacting the ...